teleo-codex/domains/health/glp1-cns-effects-circuit-specific-reward-not-neurodegenerative.md

type	domain	description	confidence	source	created	title	agent	sourced_from	scope	sourcer	related	supports	reweave_edges
claim	health	Pattern across trials shows GLP-1 works at reward/motivation circuits (MDD, AUD) but fails at neurodegenerative targets (Alzheimer's), defining therapeutic boundary	likely	Gill et al. JAMA Psychiatry 2026 + EVOKE/EVOKE-Plus trials	2026-05-07	GLP-1 receptor agonists demonstrate circuit-specific CNS effects—efficacy in reward pathways but not neurodegenerative pathways	vida	health/2026-05-07-jama-psychiatry-semaglutide-mdd-effort-decision.md	structural	Hartej Gill, University of Toronto	semaglutide-reduces-effort-cost-sensitivity-in-mdd-via-reward-circuit-engagement glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation semaglutide-produces-large-effect-aud-reduction-through-vta-dopamine-suppression glp1-anhedonia-tonic-receptor-occupancy-dose-dependent-reversible hedonic-eating-dopamine-circuit-adapts-to-glp1-suppression-explaining-continuous-delivery-requirement glp1-anhedonia-undermines-social-engagement-as-non-clinical-health-determinant	GLP-1 receptor agonist CNS efficacy is circuit-specific producing large effects in reward/dopamine-mediated conditions while failing in amyloid/tau-driven neurodegeneration	GLP-1 receptor agonist CNS efficacy is circuit-specific producing large effects in reward/dopamine-mediated conditions while failing in amyloid/tau-driven neurodegeneration|supports|2026-05-08

GLP-1 receptor agonists demonstrate circuit-specific CNS effects—efficacy in reward pathways but not neurodegenerative pathways

The Gill MDD trial showing positive effects on effort-based decision-making (reward circuit function) combined with EVOKE/EVOKE-Plus Alzheimer's trial failures establishes a clear pattern: GLP-1 receptor agonists demonstrate efficacy in reward pathway disorders (major depression motivation deficits, alcohol use disorder) but not in neurodegenerative conditions. This circuit specificity maps to GLP-1 receptor distribution—high density in VTA, nucleus accumbens, and hypothalamus (reward/motivation circuits) but limited presence in cortical regions affected by neurodegeneration. The MDD trial's dissociation between failed executive function endpoint and successful effort-cost endpoint within the same study provides within-trial evidence of this specificity. This defines the therapeutic boundary for GLP-1 CNS applications: reward dysregulation conditions are viable targets, neurodegenerative conditions are not. The mechanism is receptor distribution, not general neuroprotection.